FutureMeds and Viamed Salud, one of Spain’s leading hospital groups, signed a partnership on the 29th of November that allows FutureMeds to open 2 dedicated research sites within the well-established private hospitals in Madrid and Sevilla in early December.
With 11 hospitals, 15 health centres and 1035 beds, Viamed Salud is one of the largest private hospital groups in Spain. Since 2001, the group has delivered over 80,000 surgical procedures and 653,000 on-site consultations.
The recently signed partnership, which aims to increase trial access and diversity in clinical research in the country, enables FutureMeds to open 2 dedicated research sites within the well-established hospitals in Madrid and Sevilla early in December and help the hospital network boost their medical teams’ clinical research experience, increase revenues and improve patients’ access to new treatments.
“We see great potential for professional research sites in Spain, and our colleagues from Viamed Salud share our enthusiasm. Our collaboration with Viamed has been excellent from our very first meeting, and I am confident that we will begin our first study in Viamed hospitals within a few weeks.”
- Dr Radoslaw Janiak, CEO at FutureMeds
“Our growth in Spain is gaining momentum, and I expect this will be one of the key counties in our portfolio. Looking forward to celebrating our first randomisation in Madrid and Sevilla,” added Radoslaw Janiak.
"This is our first large-scale entry into clinical trials in the history of our hospital group. Our partnership with FutureMeds, a leading clinical trial organisation in the sector, will support us in our goal of providing added value to the population in terms of health and well-being and help improve the research capacity of our medical team.
- Paulo Gonçalves, Chief Executive Officer at Grupo Viamed Salud
"We firmly believe that research, as well as the development and production of medicines, contribute significantly to the betterment of society," added Paulo Gonçalves.
In 2021, two of Viamed’s centres embarked on running clinical trials, and so far, they have delivered 6 studies. With FutureMeds Dedicated Research Sites operating within the hospital premises, the hospital group’s experienced medical team and specialists can take advantage of more opportunities in the clinical trial field.
To deliver on commitments made by both parties, FutureMeds has 2 Pre-Selection Visits scheduled at the new Madrid and Sevilla sites for a study starting in January.
“Our partnership with Viamed Salud marks the completion of the first phase of our regional expansion. With sites in strategic locations, FutureMeds is well-positioned to make a monumental impact in the Spanish clinical research sector, boost patient care and access to innovative treatments.”
- Rocio Diaz Sanchez, Managing Director at FutureMeds Spain
With our site at Clínica DKF in Madrid and the recent Viamed additions to our network, FutureMeds now has 3 locations in Spain, further strengthening our presence and future impact in Spain's clinical research landscape.
Find more information about the new site below:
Viamed Santa Elena
FutureMeds' newest Madrid DRS will be located in Viamed Santa Elena, a 76-bed medical-surgical hospital with more than 50 years of experience offering healthcare services in the heart of the city centre. The hospital, which averages 145M outpatient visits per year, has over 350 specialists with proven experience in various therapeutic areas such as traumatology, urology, general surgery, vascular surgery, ophthalmology or neurosurgery, among others.
Viamed Fátima in Sevilla
FutureMeds Sevilla will open its doors in the Viamed Fátima Hospital located in the city centre. The 60-bed hospital inherits more than 60 years of medical tradition and averages 130M outpatient visits per year. It has over 180 specialists with extensive experience in various specialities such as traumatology, general surgery, urology, and neurosurgery.
About Viamed Salud
Viamed Salud is one of Spain’s leading hospital groups established in 2001. Their team of specialists can treat different conditions and diseases, prioritising close personal patient care with modern hospital facilities and the latest medical-surgical technology, always advocating respect and environmental sustainability.
All Viamed facilities are ISO 9001 (quality management) and UNE 179003 (patient safety) certified, with a full range of healthcare and support services provided on-site.
About FutureMeds
Specialising in conducting clinical trials, FutureMeds is the 1st European Independent Dedicated DCT Site Network offering high levels of traditional and Decentralized Clinical Trial capabilities across the whole network and home nursing solutions in 18 European countries.
FutureMeds is driven by a purpose to connect a global healthcare community and help bring quicker access to life-changing medications and therapies to all those who need it worldwide.
FutureMeds’ Dedicated Research Site (DRS) teams serve as the company's service foundation. DRS team’s execution capabilities help pharmaceutical companies and contract research organisations accelerate study timelines, streamline processes, lower costs, improve data quality and ultimately help speed up drug development and patient access to new treatments.
FutureMeds @home, the company’s Decentralized Clinical Trial solution, provides pharmaceutical companies, contract research organisations and other partners with powerful insights, tools, teams & support, enabling them to simplify patient access to trials and boost recruitment, engagement and retention.
Through its acquisitions, partnerships and a strategic focus on patient experience, FutureMeds brings opportunities to diverse European patient populations to participate in clinical research under the medical supervision of qualified physicians and health care professionals.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.